SMN2 and neuromuscular disease: Anti-sense oligonucleotides (ASO) that target the hnRNP A1 binding ISS of SMN intron 7 enhances SMN2 exon 7 inclusion, reflecting advantages in neuromuscular disease spinal muscular atrophy (Beusch et al., 2017).